Patients with treated indolent lymphomas immunized with BNT162b2 have reduced anti‐spike neutralizing IgG to SARS‐CoV‐2 variants, but preserved antigen‐specific T cell responses

Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk of severe COVID‐19. Patients and healthy controls (HC; N = 13) received two doses of BNT162b2: follicular lymphoma (FL; N = 35) who were treatment naïve (TN; N = 11) or received immunochemotherapy (ICT...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaton, Brendan, Sasson, Sarah C., Rankin, Katherine, Raedemaeker, Juliette, Wong, Alexander, Hastak, Priyanka, Phetsouphanh, Chansavath, Warden, Andrew, Klemm, Vera, Munier, C. Mee Ling, Hoppe, Alexandra Carey, Tea, Fiona, Pillay, Aleha, Stella, Alberto Ospina, Aggarwal, Anupriya, Lavee, Orly, Caterson, Ian D., Turville, Stuart, Kelleher, Anthony D., Brilot, Fabienne, Trotman, Judith
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349368/
https://www.ncbi.nlm.nih.gov/pubmed/35607995
http://dx.doi.org/10.1002/ajh.26619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349368/
https://www.ncbi.nlm.nih.gov/pubmed/35607995
http://dx.doi.org/10.1002/ajh.26619

Ejemplares similares